Bank of New York Mellon’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.53M | Sell |
296,880
-5,749
| -2% | -$136K | ﹤0.01% | 2182 |
|
|
2026
Q1 | $6.84M | Sell |
302,629
-26,987
| -8% | -$600K | ﹤0.01% | 2140 |
|
|
2025
Q4 | $8.53M | Sell |
329,616
-37,026
| -10% | -$880K | ﹤0.01% | 2020 |
|
|
2025
Q3 | $9.45M | Sell |
366,642
-19,692
| -5% | -$484K | ﹤0.01% | 1964 |
|
|
2025
Q2 | $9.23M | Buy |
386,334
+185
| +0% | +$4.66K | ﹤0.01% | 1949 |
|
|
2025
Q1 | $9.6M | Sell |
386,149
-10,250
| -3% | -$245K | ﹤0.01% | 1874 |
|
|
2024
Q4 | $7.47M | Buy |
396,399
+41,881
| +12% | +$735K | ﹤0.01% | 2078 |
|
|
2024
Q3 | $5.34M | Sell |
354,518
-45,484
| -11% | -$778K | ﹤0.01% | 2267 |
|
|
2024
Q2 | $11.4M | Buy |
400,002
+2,141
| +0.5% | +$60.9K | ﹤0.01% | 1890 |
|
|
2024
Q1 | $11.6M | Sell |
397,861
-27,358
| -6% | -$840K | ﹤0.01% | 1888 |
|
|
2023
Q4 | $14.3M | Sell |
425,219
-28,522
| -6% | -$834K | ﹤0.01% | 1779 |
|
|
2023
Q3 | $13.9M | Sell |
453,741
-16,874
| -4% | -$608K | ﹤0.01% | 1749 |
|
|
2023
Q2 | $18.9M | Sell |
470,615
-11,880
| -2% | -$491K | ﹤0.01% | 1583 |
|
|
2023
Q1 | $19.7M | Buy |
482,495
+14,942
| +3% | +$594K | ﹤0.01% | 1550 |
|
|
2022
Q4 | $18.1M | Sell |
467,553
-16,215
| -3% | -$789K | ﹤0.01% | 1592 |
|
|
2022
Q3 | $25.7M | Buy |
483,768
+9,002
| +2% | +$501K | 0.01% | 1349 |
|
|
2022
Q2 | $27.7M | Sell |
474,766
-38,179
| -7% | -$2.5M | 0.01% | 1351 |
|
|
2022
Q1 | $39.1M | Buy |
512,945
+15,960
| +3% | +$1.06M | 0.01% | 1262 |
|
|
2021
Q4 | $29.9M | Buy |
496,985
+18,825
| +4% | +$1.04M | 0.01% | 1479 |
|
|
2021
Q3 | $26.8M | Buy |
478,160
+5,472
| +1% | +$315K | 0.01% | 1554 |
|
|
2021
Q2 | $28.7M | Sell |
472,688
-10,629
| -2% | -$673K | 0.01% | 1525 |
|
|
2021
Q1 | $33.9M | Sell |
483,317
-2,452
| -0.5% | -$175K | 0.01% | 1382 |
|
|
2020
Q4 | $29.1M | Sell |
485,769
-26,601
| -5% | -$1.56M | 0.01% | 1400 |
|
|
2020
Q3 | $30.8M | Sell |
512,370
-11,261
| -2% | -$654K | 0.01% | 1189 |
|
|
2020
Q2 | $27.5M | Buy |
523,631
+32,395
| +7% | +$1.35M | 0.01% | 1237 |
|
|
2020
Q1 | $16.5M | Sell |
491,236
-8,024
| -2% | -$333K | 0.01% | 1413 |
|
|
2019
Q4 | $22.6M | Buy |
499,260
+6,383
| +1% | +$271K | 0.01% | 1495 |
|
|
2019
Q3 | $18.8M | Buy |
492,877
+280,165
| +132% | +$11.2M | 0.01% | 1565 |
|
|
2019
Q2 | $9.25M | Sell |
212,712
-5,986
| -3% | -$254K | ﹤0.01% | 2001 |
|
|
2019
Q1 | $8.32M | Buy |
218,698
+8,362
| +4% | +$326K | ﹤0.01% | 2066 |
|
|
2018
Q4 | $9.05M | Sell |
210,336
-11,646
| -5% | -$544K | ﹤0.01% | 1963 |
|
|
2018
Q3 | $10.9M | Sell |
221,982
-304
| -0.1% | -$13.1K | ﹤0.01% | 1971 |
|
|
2018
Q2 | $7.13M | Sell |
222,286
-3,789
| -2% | -$131K | ﹤0.01% | 2197 |
|
|
2018
Q1 | $7.04M | Buy |
226,075
+2,918
| +1% | +$104K | ﹤0.01% | 2172 |
|
|
2017
Q4 | $10.2M | Sell |
223,157
-12,901
| -5% | -$511K | ﹤0.01% | 1975 |
|
|
2017
Q3 | $8.87M | Buy |
236,058
+17,971
| +8% | +$723K | ﹤0.01% | 2047 |
|
|
2017
Q2 | $10.4M | Buy |
218,087
+11,652
| +6% | +$541K | ﹤0.01% | 1945 |
|
|
2017
Q1 | $9.41M | Buy |
206,435
+8,366
| +4% | +$362K | ﹤0.01% | 2007 |
|
|
2016
Q4 | $6.4M | Buy |
198,069
+8,308
| +4% | +$277K | ﹤0.01% | 2188 |
|
|
2016
Q3 | $6.49M | Buy |
189,761
+6,926
| +4% | +$271K | ﹤0.01% | 2107 |
|
|
2016
Q2 | $6.17M | Sell |
182,835
-18,234
| -9% | -$896K | ﹤0.01% | 2102 |
|
|
2016
Q1 | $10.7M | Sell |
201,069
-25,540
| -11% | -$1.49M | ﹤0.01% | 1807 |
|
|
2015
Q4 | $17.4M | Buy |
226,609
+32,355
| +17% | +$1.83M | 0.01% | 1475 |
|
|
2015
Q3 | $7.98M | Sell |
194,254
-26,637
| -12% | -$1.63M | ﹤0.01% | 1982 |
|
|
2015
Q2 | $15.6M | Sell |
220,891
-176,192
| -44% | -$13.9M | ﹤0.01% | 1654 |
|
|
2015
Q1 | $35.3M | Sell |
397,083
-214,606
| -35% | -$21.8M | 0.01% | 1101 |
|
|
2014
Q4 | $54.2M | Buy |
611,689
+396,300
| +184% | +$37.5M | 0.01% | 850 |
|
|
2014
Q3 | $20.9M | Sell |
215,389
-250,029
| -54% | -$24.3M | 0.01% | 1399 |
|
|
2014
Q2 | $42.8M | Sell |
465,418
-20,842
| -4% | -$1.59M | 0.01% | 999 |
|
|
2014
Q1 | $34M | Sell |
486,260
-478,690
| -50% | -$32.6M | 0.01% | 1124 |
|
|
2013
Q4 | $55.5M | Buy |
964,950
+628,724
| +187% | +$33.1M | 0.02% | 834 |
|
|
2013
Q3 | $16.2M | Buy |
336,226
+196,944
| +141% | +$7.18M | ﹤0.01% | 1545 |
|
|
2013
Q2 | $4.04M | Buy |
+139,282
| New | +$4.03M | ﹤0.01% | 2331 |
|
Other funds holding PCRX
GS
GA
EIP
HWAM
Bank of New York Mellon's PCRX Position: Q2 2026 in Review
Bank of New York Mellon reduced its Pacira BioSciences (PCRX) stake by 1.9% in Q2 2026, selling an estimated $136K and leaving 296,880 shares worth $7.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2182.
Bank of New York Mellon first reported a position in PCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $55.5M in Q4 2013. 101 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Bank of New York Mellon held 296,880 shares of Pacira BioSciences worth $7.53M as of Q2 2026.
- Bank of New York Mellon sold 5,749 Pacira BioSciences shares in Q2 2026, an estimated $136K.
- Pacira BioSciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2182 holding.
- Bank of New York Mellon first reported a position in Pacira BioSciences in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Pacira BioSciences position peaked at $55.5M in Q4 2013.
- 101 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.